Antares Gets Notice Of Allowance For New Patent On Lyophilized Injectables

(RTTNews) - Antares Pharma Inc. (ATRS), Friday said it received a Notice of Allowance from the U.S. Patent Office for a patent that relates to its injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

The designs described in the application result in the injector performing the reconstitution of the dry drugs into an injectable liquid form and then perform the injection similar to the Antares VIBEX and QuickShot devices. Adding the reconstitution mechanism to the base of the VIBEX and QuickShot injection platform allows Antares to build on its technology platform on which OTREXUP was developed. The expiry date for the patent issued in August of 2012 is 2028.

Paul Wotton, President and CEO said: "We are developing a pipeline of injectable products, designed for use in a home care setting and we have extended our intellectual property to reconstitutable drugs, including those biological agents where high viscosity may be a challenge for device technologies less innovative than our VIBEX or QuickShot systems."